Clinical Trials

Blastic Plasmacytoid Dendritic Cell Neoplasm, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07527221 2026-06-01

Safety and Tolerability of ZE74-0282 in Healthy Volunteers

40 enrolled

Polycythemia, Thrombocythemia, Essential, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Primary Myelofibrosis

NCT06092879 2026-05-29

ASSURE-3

Active not recruiting

201 enrolled

Phase 3 Active not recruiting

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05456191 2026-05-27

ASC4START

568 enrolled 11 charts

Leukemia, Myeloproliferative Disorders, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07354074 2026-05-26

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

Phase 2 Recruiting

50 enrolled

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05362773 2026-05-22

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

130 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Hairy Cell, Myelodysplastic Syndromes, Leukemia, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Mastocytosis, Systemic

NCT07454850 2026-05-18

A Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in Kuwait

Not yet recruiting

400 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT07549516 2026-05-15

ASC2ADHERE

380 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02629692 2026-05-13

Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

Phase 1/2 Terminated

124 enrolled 51 charts

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04877522 2026-05-11

Asciminib Roll-over Study

Phase 4 Recruiting

347 enrolled

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04925479 2026-04-30

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

Phase 1/2 Recruiting

34 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03578367 2026-04-21

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

104 enrolled 33 charts

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06514534 2026-04-21

ASC4TARGET

Phase 2 Recruiting

20 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05943522 2026-04-20

Asciminib RMP Study

600 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06427811 2026-04-17

ASC4INDIA

Phase 4 Completed

85 enrolled

Bronchiolitis Obliterans Syndrome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06297161 2026-04-14

A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).

600 enrolled

Phase 3 Active not recruiting

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04971226 2026-04-06

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

405 enrolled 18 charts 1 FDA

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03874858 2026-04-02

DANTE

124 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT05304377 2026-04-01

CML

250 enrolled

Phase 3 Not yet recruiting

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT07489755 2026-03-24

TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients

180 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT04948333 2026-03-18

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP

Phase 3 Completed

199 enrolled 13 charts

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02467270 2026-03-17

OPTIC

283 enrolled 31 charts

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT06994676 2026-03-16

CROSSCHECK-001

72 enrolled

125 enrolled 18 charts 1 FDA

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02730299 2026-02-25

Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS

Phase 3 Completed

Classical hematologyDermatologicLymphoidMyeloidOther hematologic neoplasm

Lymphoma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05589896 2026-02-24

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

Phase 1/2 Recruiting

12 enrolled

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Hodgkin Disease, Leukemia, Lymphoma, Leukemia, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Cutaneous, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06163430 2026-01-12

CARDINAL

Phase 1/2 Recruiting

180 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT04360005 2025-12-05

Managed Access Programs for ABL001, Asciminib

Available

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04260022 2025-11-05

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

242 enrolled

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Burkitt Lymphoma, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03320642 2025-10-21

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Phase 1 Terminated

84 enrolled

Anemia, Refractory, with Excess of Blasts, Graft vs Host Disease, Hodgkin Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT07188428 2025-09-23

Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment

Completed

2,298 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01784068 2025-09-10

ENESTfreedom

215 enrolled 7 charts 1 FDA

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06986772 2025-09-04

TGRX-678 Pharmacokinetic Mass Balance

Phase 1 Completed

6 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07151820 2025-09-03

A Real-world Study About the Impact of Adverse Events (AEs) on Treatment Adjustments, Healthcare Resource Use, and Costs Among Chronic Myeloid Leukemia Patients

Completed

2,546 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01698905 2025-09-02

ENESTop

163 enrolled 7 charts 1 FDA

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07150793 2025-09-02

A Study of Real-world Treatment and Burden of Chronic Myeloid Leukemia Patients in Japan

Completed

754 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07145411 2025-08-28

HOPE

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

10 enrolled

Anemia, Aplastic, Anemia, Sickle Cell, Lymphoma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06787144 2025-07-01

CML

21 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT01290302 2025-06-12

Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza

Phase 1 Completed

38 enrolled 14 charts